Avonex:
- Treatment of patients with relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis
- Treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability
- Treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis
- For the treatment of patients with relapsing-forms of multiple sclerosis.
- Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses)
- In combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer
- In combination with corticosteroids as initial therapy of acute nonlymphocytic leukemia in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias
- Treatment of patients with relapsing forms of multiple sclerosis
- Treatment of patients with relapsing forms of multiple sclerosis
- Treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
Plegridy:
- Treatment of patients with relapsing forms of multiple sclerosis
- Treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.